S&P 500   4,280.15 (+1.73%)
DOW   33,761.05 (+1.27%)
QQQ   330.48 (+1.97%)
AAPL   172.07 (+2.12%)
MSFT   291.80 (+1.67%)
META   180.27 (+1.57%)
GOOGL   121.63 (+2.35%)
AMZN   143.45 (+2.00%)
TSLA   900.00 (+4.66%)
NVDA   187.27 (+4.38%)
NIO   21.07 (+1.20%)
BABA   94.64 (-0.24%)
AMD   100.77 (+2.70%)
MU   64.94 (+4.20%)
T   18.23 (+1.05%)
CGC   3.30 (+4.76%)
GE   79.94 (+1.32%)
F   16.18 (+2.21%)
DIS   121.45 (+3.19%)
AMC   24.52 (-3.69%)
PYPL   100.92 (+1.83%)
PFE   50.11 (+3.77%)
NFLX   248.83 (+2.53%)
S&P 500   4,280.15 (+1.73%)
DOW   33,761.05 (+1.27%)
QQQ   330.48 (+1.97%)
AAPL   172.07 (+2.12%)
MSFT   291.80 (+1.67%)
META   180.27 (+1.57%)
GOOGL   121.63 (+2.35%)
AMZN   143.45 (+2.00%)
TSLA   900.00 (+4.66%)
NVDA   187.27 (+4.38%)
NIO   21.07 (+1.20%)
BABA   94.64 (-0.24%)
AMD   100.77 (+2.70%)
MU   64.94 (+4.20%)
T   18.23 (+1.05%)
CGC   3.30 (+4.76%)
GE   79.94 (+1.32%)
F   16.18 (+2.21%)
DIS   121.45 (+3.19%)
AMC   24.52 (-3.69%)
PYPL   100.92 (+1.83%)
PFE   50.11 (+3.77%)
NFLX   248.83 (+2.53%)
S&P 500   4,280.15 (+1.73%)
DOW   33,761.05 (+1.27%)
QQQ   330.48 (+1.97%)
AAPL   172.07 (+2.12%)
MSFT   291.80 (+1.67%)
META   180.27 (+1.57%)
GOOGL   121.63 (+2.35%)
AMZN   143.45 (+2.00%)
TSLA   900.00 (+4.66%)
NVDA   187.27 (+4.38%)
NIO   21.07 (+1.20%)
BABA   94.64 (-0.24%)
AMD   100.77 (+2.70%)
MU   64.94 (+4.20%)
T   18.23 (+1.05%)
CGC   3.30 (+4.76%)
GE   79.94 (+1.32%)
F   16.18 (+2.21%)
DIS   121.45 (+3.19%)
AMC   24.52 (-3.69%)
PYPL   100.92 (+1.83%)
PFE   50.11 (+3.77%)
NFLX   248.83 (+2.53%)
S&P 500   4,280.15 (+1.73%)
DOW   33,761.05 (+1.27%)
QQQ   330.48 (+1.97%)
AAPL   172.07 (+2.12%)
MSFT   291.80 (+1.67%)
META   180.27 (+1.57%)
GOOGL   121.63 (+2.35%)
AMZN   143.45 (+2.00%)
TSLA   900.00 (+4.66%)
NVDA   187.27 (+4.38%)
NIO   21.07 (+1.20%)
BABA   94.64 (-0.24%)
AMD   100.77 (+2.70%)
MU   64.94 (+4.20%)
T   18.23 (+1.05%)
CGC   3.30 (+4.76%)
GE   79.94 (+1.32%)
F   16.18 (+2.21%)
DIS   121.45 (+3.19%)
AMC   24.52 (-3.69%)
PYPL   100.92 (+1.83%)
PFE   50.11 (+3.77%)
NFLX   248.83 (+2.53%)
NASDAQ:ARDX

Ardelyx - ARDX Stock Forecast, Price & News

$0.91
+0.02 (+1.76%)
(As of 08/12/2022 03:59 PM ET)
Add
Compare
Today's Range
$0.89
$0.94
50-Day Range
$0.51
$0.91
52-Week Range
$0.49
$1.92
Volume
42,358 shs
Average Volume
1.51 million shs
Market Capitalization
$140.71 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.20

Ardelyx MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
431.2% Upside
$4.83 Price Target
Short Interest
Bearish
7.04% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.98
Upright™ Environmental Score
News Sentiment
0.31mentions of Ardelyx in the last 14 days
Based on 14 Articles This Week
Insider Trading
Selling Shares
$153,157 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.70) to ($0.36) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.08 out of 5 stars

Medical Sector

663rd out of 1,117 stocks

Pharmaceutical Preparations Industry

331st out of 550 stocks

ARDX stock logo

About Ardelyx (NASDAQ:ARDX) Stock

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial to control serum phosphorus in adult patients with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia. It is also developing RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease; and RDX020, an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD. The company has agreements with Kyowa Kirin in Japan, Fosun Pharmaceutical Industrial Development Co. Ltd. in China, and Knight Therapeutics, Inc. in Canada for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Wall Street Analyst Weigh In

Several analysts have commented on ARDX shares. Cantor Fitzgerald lowered shares of Ardelyx from an "overweight" rating to a "neutral" rating and decreased their price target for the company from $7.00 to $1.00 in a research report on Friday, May 6th. StockNews.com lowered shares of Ardelyx from a "hold" rating to a "sell" rating in a research report on Saturday, August 6th. Piper Sandler decreased their price target on shares of Ardelyx from $4.00 to $3.00 and set a "neutral" rating for the company in a research report on Wednesday, May 18th. Finally, Wedbush restated a "neutral" rating on shares of Ardelyx in a report on Friday, August 5th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and three have given a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus target price of $4.83.

Ardelyx Stock Down 1.7 %

Shares of ARDX traded down $0.02 during mid-day trading on Thursday, hitting $0.89. 2,386,720 shares of the company traded hands, compared to its average volume of 3,029,447. Ardelyx has a 1-year low of $0.49 and a 1-year high of $1.92. The company has a market capitalization of $138.28 million, a PE ratio of -0.79 and a beta of 1.84. The business has a 50 day moving average of $0.67 and a 200 day moving average of $0.78.

Ardelyx (NASDAQ:ARDX - Get Rating) last issued its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.19) earnings per share for the quarter, hitting the consensus estimate of ($0.19). Ardelyx had a negative net margin of 2,594.88% and a negative return on equity of 191.74%. During the same period in the prior year, the firm posted ($0.45) EPS. As a group, research analysts expect that Ardelyx will post -0.7 EPS for the current fiscal year.

Insider Buying and Selling

In related news, insider Susan Rodriguez sold 43,920 shares of the stock in a transaction that occurred on Monday, June 6th. The shares were sold at an average price of $0.65, for a total value of $28,548.00. Following the transaction, the insider now owns 289,593 shares in the company, valued at approximately $188,235.45. The sale was disclosed in a filing with the SEC, which is available through this link. In other Ardelyx news, insider Susan Rodriguez sold 43,920 shares of the company's stock in a transaction that occurred on Monday, June 6th. The stock was sold at an average price of $0.65, for a total value of $28,548.00. Following the sale, the insider now owns 289,593 shares in the company, valued at approximately $188,235.45. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Michael Raab sold 103,624 shares of the stock in a transaction that occurred on Monday, June 6th. The shares were sold at an average price of $0.65, for a total value of $67,355.60. Following the transaction, the chief executive officer now owns 668,826 shares in the company, valued at approximately $434,736.90. The disclosure for this sale can be found here. In the last quarter, insiders have sold 235,185 shares of company stock worth $153,157. 6.00% of the stock is owned by company insiders.

Receive ARDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ardelyx and its competitors with MarketBeat's FREE daily newsletter.

ARDX Stock News Headlines

Wedbush Reiterates Neutral Rating for Ardelyx (NASDAQ:ARDX)
StockNews.com Downgrades Ardelyx (NASDAQ:ARDX) to Sell
Analysts Set Ardelyx, Inc. (NASDAQ:ARDX) Target Price at $4.83
See More Headlines
Receive ARDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ardelyx and its competitors with MarketBeat's FREE daily newsletter.

ARDX Company Calendar

Last Earnings
8/04/2022
Today
8/12/2022
Next Earnings (Estimated)
11/11/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ARDX
Employees
86
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$4.83
High Stock Price Forecast
$13.00
Low Stock Price Forecast
$1.00
Forecasted Upside/Downside
+251.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
6 Analysts

Profitability

Net Income
$-158,160,000.00
Net Margins
-2,594.88%
Pretax Margin
-2,594.71%

Debt

Sales & Book Value

Annual Sales
$10.10 million
Book Value
$0.34 per share

Miscellaneous

Free Float
145,358,000
Market Cap
$140.71 million
Optionable
Optionable
Beta
1.84














ARDX Stock - Frequently Asked Questions

Should I buy or sell Ardelyx stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ardelyx in the last year. There are currently 3 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ARDX shares.
View ARDX analyst ratings
or view top-rated stocks.

What is Ardelyx's stock price forecast for 2022?

6 brokers have issued 12 month price objectives for Ardelyx's shares. Their ARDX share price forecasts range from $1.00 to $13.00. On average, they expect the company's share price to reach $4.83 in the next year. This suggests a possible upside of 417.5% from the stock's current price.
View analysts price targets for ARDX
or view top-rated stocks among Wall Street analysts.

How have ARDX shares performed in 2022?

Ardelyx's stock was trading at $1.10 at the beginning of 2022. Since then, ARDX stock has decreased by 15.1% and is now trading at $0.9340.
View the best growth stocks for 2022 here
.

When is Ardelyx's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, November 11th 2022.
View our ARDX earnings forecast
.

How were Ardelyx's earnings last quarter?

Ardelyx, Inc. (NASDAQ:ARDX) issued its quarterly earnings results on Thursday, August, 4th. The biopharmaceutical company reported ($0.19) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.19). Ardelyx had a negative trailing twelve-month return on equity of 191.74% and a negative net margin of 2,594.88%. During the same period last year, the business posted ($0.45) earnings per share.

What other stocks do shareholders of Ardelyx own?

What is Ardelyx's stock symbol?

Ardelyx trades on the NASDAQ under the ticker symbol "ARDX."

Who are Ardelyx's major shareholders?

Ardelyx's stock is owned by many different retail and institutional investors. Top institutional investors include Franklin Resources Inc. (0.13%), Group One Trading L.P. (0.00%), Simplex Trading LLC (0.00%) and Assenagon Asset Management S.A. (0.05%). Insiders that own company stock include David M Mott, David P Rosenbaum, Elizabeth A Grammer, Elizabeth A Grammer, Forest Baskett, Jeffrey W Jacobs, Jeffrey W Jacobs, Justin A Renz, Mark Kaufmann, Michael Raab, Robert Blanks, Scott D Sandell and Susan Rodriguez.
View institutional ownership trends
.

How do I buy shares of Ardelyx?

Shares of ARDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ardelyx's stock price today?

One share of ARDX stock can currently be purchased for approximately $0.93.

How much money does Ardelyx make?

Ardelyx (NASDAQ:ARDX) has a market capitalization of $144.43 million and generates $10.10 million in revenue each year. The biopharmaceutical company earns $-158,160,000.00 in net income (profit) each year or ($1.13) on an earnings per share basis.

How can I contact Ardelyx?

Ardelyx's mailing address is 34175 ARDENWOOD BOULEVARD SUITE 200, FREMONT CA, 94555. The official website for the company is www.ardelyx.com. The biopharmaceutical company can be reached via phone at (510) 745-1700, via email at investor@ardelyx.com, or via fax at 510-745-0493.

This page (NASDAQ:ARDX) was last updated on 8/12/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.